Frontlight ResearchEarly access
Pompe disease trials in Germany
5 of 9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
- Where
- Halle (Saale), Hochheim Am Main, Munich
- Age
- 18 years to 64 years
- People
- 21 worldwide
- Run by
- Shionogi B.V.
See details and how to join2025-522146-40-00 - Phase 1Taking peopleA Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
- Where
- Hochheim Am Main
- Age
- 18 years to 75 years
- People
- 32 worldwide
- Run by
- Denali Therapeutics Inc.
See details and how to joinNCT07354724 · EU 2025-524082-25-00 - Phase 2Taking peopleStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
- Where
- Halle, Höchheim, München
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- Shionogi
See details and how to joinNCT07123155 - Phase 3Taking peopleA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
- Where
- Giessen, Heidelberg, Hochheim Am Main, Münster
- Age
- Up to 17 years
- People
- 36 worldwide
- Run by
- Amicus Therapeutics
See details and how to joinNCT04808505 · EU 2022-501095-25-01 - No phaseEnrolling by invitationThe Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
- Where
- Bad Feilnbach
- Age
- 65 years to 65 years
- People
- 30
- Run by
- LMU Klinikum
See details and how to joinNCT07072676